Back
Sep 28
Education

EDU 05 - Androgen Deprivation Therapy and Dose Escalation for Prostate Cancer: Lessons from Randomized Trials and the MARCAP Consortium

02:45pm - 04:00pm PT
Genitourinary Cancer

MODERATOR(S)

Amar Kishan, MD, PhD - UCLA

session DESCRIPTION

Numerous randomized trials have studied the benefit of adding androgen deprivation therapy (ADT) and/or prolonging its duration when treating localized prostate cancer with radiotherapy, while other trials have interrogated the benefit of escalating radiotherapy dose itself. These trials have varied considerably in the sequencing of ADT that was used. Based on the successes of individual patient data meta-analyses in quantifying the benefit of adding postoperative radiotherapy for breast cancer patients and determining the optimal sequencing of chemotherapy and radiation for head and neck cancer patients, the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium was founded to better quantify the benefits of dose escalation and ADT use, duration, and sequencing. The MARCAP Consortium additionally provided information to evaluate the kinetics of testosterone recovery after ADT and potential oncologic implications, as well as the clinical importance of various endpoints after definitive treatment. This 90-minute educational session will highlight and summarize completed, ongoing, and future work from the MARCAP consortium with a focus on implications for contemporary practice. Specifically, we will: (a) provide data to quantify the benefits of ADT use and prolongation as well as the benefits of dose escalation, (b) evaluate and identify the optimal sequencing of ADT with radiotherapy, (c) discuss testosterone recovery after ADT and implications for treatment outcome, and (d) discuss the endpoint of biochemical recurrence and its clinical and practical significance.

learning objectives

  1. Quantify the benefits of adding hormonal therapy versus increasing radiation for the definitive management of localized prostate cancer.
  2. Discuss the oncological impact of varying the sequencing of androgen deprivation therapy with radiation, as well as the kinetics of testosterone recovery.
  3. Discuss key oncologic endpoints and their significance for patients treated with radiotherapy for prostate cancer.

Credits

AMA PRA Category 1 Credits: 1.25

Presentations